RECURSION PHARMACEUTICALS, INC. Accounts Payable
RECURSION PHARMACEUTICALS, INC. (RXRX) had Accounts Payable of $12.67 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-05
- 2026-06-30: Accounts Payable, Current $12.67M.
- 2026-03-31: Accounts Payable, Current $20.35M.
- 2025-12-31: Accounts Payable, Current $18.12M.
- 2025-09-30: Accounts Payable, Current $13.94M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $12.67M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $20.35M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $18.12M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $13.94M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $19.31M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $25.09M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $21.61M 10-K · filed 2026-02-25 |
| 2024-09-30 | $2.26M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $3.76M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $5.12M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $3.95M 10-K · filed 2025-02-28 |
| 2023-09-30 | $4.26M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.09M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $4.25M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $4.59M 10-K · filed 2024-02-29 |
| 2022-09-30 | $3.89M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $3.18M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $4.16M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $2.82M 10-K · filed 2023-02-27 |
| 2021-09-30 | $6.33M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $3.20M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $3.13M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $1.07M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |